Combination therapies with disulfiram
Disclosed herein are compositions and methods for increasing lifespan, for preventing or treating a disease including an aging-related disorder, for reducing a symptom of aging, and/or boosting an immune system in a mammal. Also disclosed herein are compositions and methods for improving effectiveness of a vaccine in a mammal. The compositions comprise, at least, a therapeutically effective amount of disulfiram and one or more additional ingredients.
1. A method for inhibiting and/or reducing pyroptotic cell death in a cell, the method comprising contacting the cell with an active agent that is disulfiram and a potentiating ingredient that is tert-Butylhydroquinone (TBHQ), thereby inhibiting and/or reducing pyroptotic cell death, wherein the amount of disulfiram is from about 5 mg to about 500 mg and the amount of TBHQ is from about 0.02% to about 56% by weight of disulfiram and a combination of disulfiram and TBHQ provides a synergistic effect.
2. The method of claim 1 , wherein disulfiram and TBHQ are included in one composition and the composition consists essentially of disulfiram and TBHQ.
3. The method of claim 1 , wherein the method comprises contacting the cell with a first composition consisting essentially of disulfiram and contacting the cell with a second composition consisting essentially TBHQ.
4. The method of claim 1 , wherein inhibiting and/or reducing pyroptotic cell death in the cell increases the lifespan of the cell.
5. A method for inhibiting and/or reducing pyroptotic cell death in a cell, the method comprising contacting the cell with an active agent that is disulfiram and a potentiating ingredient that is tert-Butylhydroquinone (TBHQ), thereby inhibiting and/or reducing pyroptotic cell death, wherein the amount of disulfiram is from about 5 mg to about 500 mg and the amount of TBHQ is from about 0.02% to about 56% by weight of disulfiram and a combination of disulfiram and TBHQ provides a synergistic effect, wherein the combination of disulfiram and TBHQ treats acute lung injury (ALI), acute respiratory distress syndrome (ARDS), idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, dry eye, actinic keratosis, alopecia, and/or skin cancer.
6. The method of claim 1 , wherein the combination of disulfiram and TBHQ inhibits and/or reduces a pathological inflammatory response, alters a T-cell's age, and/or alters mitochondrial function in the cell.
7. A method for boosting activity of an immune cell, the method comprising contacting the immune cell with an active agent that is disulfiram and a potentiating ingredient that is tert-Butylhydroquinone (TBHQ), thereby boosting activity of the immune cell, wherein the amount of disulfiram is from about 5 mg to about 500 mg and the amount of TBHQ is from about 0.02% to about 56% by weight of disulfiram and a combination of disulfiram and TBHQ provides a synergistic effect.
8. The method of claim 7 , wherein disulfiram and TBHQ are included in one composition and the composition consists essentially of disulfiram and TBHQ.
9. The method of claim 7 , wherein the method comprises contacting the immune cell with a first composition consisting essentially of disulfiram and contacting the cell with an at least second composition consisting essentially TBHQ.
10. The method of claim 7 , wherein boosting activity of the immune cell increases an effective immune response against an infectious agent and/or an atypical cell.
11. The method of claim 7 , wherein boosting activity of the immune cell improves the immune cell's response against a component contained in a vaccine, wherein the component contained in the vaccine is an antigen obtained from, related to, homologous to, or expressed by an infectious agent.
12. The method of claim 7 , wherein boosting activity of the immune cell comprises inhibiting a pathological immune response.
13. The method of claim 12 , wherein boosting activity of the immune cell minimizes overactive immune cell activity.
14. The method of claim 1 , wherein the synergistic effect is characterized using a Synergy Fold Ratio and/or using the Loewe Additivity Model.
15. The method of claim 7 , wherein the synergistic effect is characterized using a Synergy Fold Ratio and/or using the Loewe Additivity Model.
16. The method of claim 5 , wherein disulfiram and TBHQ are included in one composition and the composition consists essentially of disulfiram and TBHQ.
17. The method of claim 5 , wherein the method comprises contacting the cell with a first composition consisting essentially of disulfiram and contacting the cell with an at least second composition consisting essentially TBHQ.
18. The method of claim 5 , wherein the synergistic effect is characterized using a Synergy Fold Ratio and/or using the Loewe Additivity Model.